Axon Enterprise, Inc.

Axon Enterprise completed a $1.15B offering of 0% Convertible Senior Notes due September 15, 2031, including the full $150M over-allotment exercised by underwriters. The notes carry no regular cash interest and convert at an initial rate of 1.5336 shares per $1,000 principal, implying a conversion price of approximately $652.06 per share — a significant premium to the prevailing stock price. Proceeds will be used for general corporate purposes including potential acquisitions and share repurchases.

Axon Enterprise (AXON) is offering $1,000,000,000 principal amount of 0% Convertible Senior Notes due September 15, 2031, pursuant to Rule 424(b)(5). The notes bear no regular interest and are convertible into common stock at holders' option prior to June 15, 2031 under specified stock-price and trading-price triggers (including ≥130% of conversion price for 20 of 30 days). Axon may optionally redeem the notes on or after September 20, 2028 and must redeem in cleanup scenarios. This is a material $1B dilutive event — a zero-coupon convertible structure that defers cash interest while creating future equity dilution, funded for general corporate purposes.

Axon Enterprise (AXON) launched a preliminary $1.0B offering of 0% Convertible Senior Notes due September 15, 2031, via a 424B5 prospectus supplement. The zero-coupon notes convert into cash, shares, or a combination at Axon's election; conversion price not yet disclosed in the preliminary. An active dilutive capital raise — zero-coupon convertible offering targeting institutional arbitrage demand, with full dilution terms to be set at final pricing.

Axon Enterprise (AXON) entered into a Second Amendment to its credit agreement with JPMorgan Chase as administrative agent, conditioned on closing of the concurrent $1B convertible notes offering. The amendment increases the revolving credit facility from $300M to $500M (with option for $150M more) and extends maturity to approximately September 18, 2031. Combined with the convertible offering, Axon is executing a major liquidity expansion — increasing revolving capacity by 67% alongside $1B of long-term zero-coupon debt.

Eiso Kant filed a Form 3 as a newly appointed director of Axon Enterprise, Inc. (effective July 8, 2026), disclosing direct beneficial ownership of 2,565 shares of common stock acquired in open-market transactions prior to his appointment and before becoming subject to Section 16 reporting. No derivative securities are held. This is a routine initial-ownership disclosure with no current-day market impact.

Vivek Mohindra filed a Form 3 upon his appointment as a director of Axon Enterprise, Inc. effective July 8, 2026, reporting no beneficial ownership of Axon securities at the time of the filing. No direct or indirect holdings of common stock or derivative securities are disclosed. Routine initial-ownership statement; immaterial to the market.

Axon Enterprise appointed two new independent directors on July 8, 2026: Vivek Mohindra, who joined the Audit and Compensation Committees, and Eiso Kant, who serves as a non-voting observer on the Mergers & Acquisitions and Capital Structure Committee. Both have initial terms expiring at Axon's 2027 annual meeting. The board expansion broadens governance coverage across financial oversight and M&A, an administrative but constructive signal given Axon's active capital-deployment profile.

Axon Enterprise held its 2026 Annual Meeting on May 28, 2026; 72.9 million shares (approximately 90.5% of 80.6M outstanding) were voted on director elections, say-on-pay, and auditor ratification. Routine annual meeting with very high shareholder participation.